COVID-19 vaccines appear to work against the new coronavirus strains, though scientists are warily watching a variant first seen in South Africa. Vaccines may need updates to keep pace with the virus.
I haven't seen my mother in over a year. I was going to visit in April to celebrate her 90th birthday but the pandemic put that on hold. Now that she's been vaccinated is it time for the birthday hug?
The administration is in its early days, but the infectious disease expert says he's encouraged by the new president's attitude about the pandemic. Science, Fauci says, is "going to rule."
With vaccine still scarce, and eligibility differing from place to place, some people have easier access to "extra" doses than others. Careful, ethicists warn. Going out of turn is a slippery slope.
A new model estimates how many new infections are missed by testing and how many people are actively shedding the virus. The numbers are staggering and lend urgency to the vaccine race.
Supply shortages of oxygen for hospitals have plagued many countries, but the U.S. has averted the most dire — partly because the industry figured out new ways to share resources and anticipate needs.
The spread of new strains raises new questions as two COVID-19 vaccines continue their rollout across the U.S. and another vaccine candidate preps for regulatory review. Here's what you need to know.
The two companies producing COVID-19 vaccines for use in the United States will have to raise production to meet contractual goals of 100 million doses each by the end of March.
The Georgia governor's office says public health departments and other providers are being forced to “pause" appointments for people hoping to get vaccinated against the coronavirus in the Cobb-Douglas counties district.
Dr. Paul Stoffels, the chief scientific officer at Johnson & Johnson, tells NPR the company's vaccine is very effective where it matters most: preventing hospitalizations and deaths.
Large corporations such as Starbucks, Honeywell, Microsoft, Costco and Google want to help states with planning and logistics. But the potential of these partnerships is hindered by supply problems.
The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.